glp-1 drugs glycemic control mechanism of action of [25] Drug mechanism of action of

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

Clinical Evidence for GLP-1 Receptor Agonists in Alzheimers Disease. PubMed Cheng HW et al

Primary care physicians often make decisions regarding the initiation of basal insulin in T2D, as they work closely with patients and are well placed to discuss and manage the transition to basal insulin therapy

But theres a tradeoff

Diabetesmellitus (DM) is a group of metabolic diseases classified by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both

Quality Assurance & Verification